Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells
Therapeutic Solutions International (TSOI) announced today issuance of United States Patent # 11,504,4101 which in its broadest claim covers:
“A method of protecting from damage and/or of regenerating a neurological tissue, comprising administration of: (a) pterostilbene, and/or blueberry, and/or an extract thereof; (b) green tea and/or an extract thereof; (c) Nigella sativa and/or an extract thereof; and (d) broccoli and/or an extract thereof.”
Dependent patent claims cover various mechanisms of neural protection and regeneration, as well as treatment of different pathologies which cause neural deterioration. The Company views the issuance of these claims in an extremely positive manner because they not only cover the composition of matter of its commercially available immune modulatory nutraceutical QuadraMune®, but they also cover individual ingredients that comprise QuadraMune®.
“If one searches pterostilbene, nigella sativa, sulforaphane, or EGCG, you can see that these ingredients are already used for a variety of nutraceutical applications. The fact that we have an issued patent covering their use for brain regeneration both alone and together, positions the Company strongly in this crowded space,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor on the patent. “We are in a very rare and unique situation in that after we filed the patent, numerous independent academic institutes have confirmed the biological properties of these ingredients that we covered in the patent and now have been granted to us for conceptualizing them before anyone else.”
There are many examples of the science behind QuadraMune® being confirmed by independent groups. One example was the work of Johns Hopkins University which showed COVID-19 virus inhibition by one of the ingredients in QuadraMune® after the Company filing its patents2. This is the third patent issued surrounding QuadraMune® and its ingredients. The first covered therapeutic immune modulation and inhibition of the immune suppressive enzyme indolamine 2,3 deoxygenase (#11,229,6743), and the second patent covered the prevention and treatment of COVID-19 (#11,266,7074).
“As a Company, our main mission is to hyper-accelerate scientific and corporate progress which is essential for delivering life-saving medicine to patients who have no other options. Whether it is successful treatment of epilepsy5, Emergency INDs for treatment of COVID-196, or treatment of cancer patients with ValloVax7, we are happy for the support our efforts are receiving,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “The granting of these broad claims in our recently issued patent provides strong support for the scientific innovation of our work and we believe will accelerate our commercial and patient success.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
1 Neuroprotection and neuroregeneration by pterostilbene and compositions thereof
2 John Hopkin’s University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies
3 Nutraceuticals for suppressing indolamine 2,3 deoxygenase
4 Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19
5 Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient
6 Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial
7 Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy
Timothy G. Dixon